

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Fukumura *et al.*

Art Unit: 1636

Appl. No: 09/720,979 (U.S. National Stage of
PCT/JP99/03552)

Examiner: to be assigned

International Filing Date: July 1, 1999

Atty. Docket: 4001-0003

For: **Negative-Sense RNA Virus Vector for
Nerve Cell**

**STATEMENT TO SUPPORT FILING AND SUBMISSION OF SUBSTITUTE
SEQUENCE LISTING IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a substitute Sequence Listing submitted concurrently herewith,
the undersigned hereby states that:

1. the substitute submission filed herewith in accordance with 37 C.F.R. §§ 1.821(g) and 1.825(a), does not include new matter, it simply clarifies the definitions of SEQ ID NOS: 1-3. Support for the substitute submission is found in, for example, Figure 1;

2. the content of the attached paper copy and the attached computer readable copy of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same as required by 37 C.F.R. § 1.821(f); and

3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these

statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

SHANKS & HERBERT

By: Mark R. Shanks
Mark R. Shanks
Reg. No. 33,781

Date: 4/16/02

TransPotomac Plaza
1033 N. Fairfax Street
Suite 306
Alexandria, VA 22314
(703) 683-3600